Aytu Biopharma Inc banner

Aytu Biopharma Inc
NASDAQ:AYTU

Watchlist Manager
Aytu Biopharma Inc Logo
Aytu Biopharma Inc
NASDAQ:AYTU
Watchlist
Price: 2.61 USD 1.16% Market Closed
Market Cap: $28m

Wall St Price Targets

AYTU Price Targets Summary
Aytu Biopharma Inc

Wall Street analysts forecast AYTU stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AYTU is 9.52 USD with a low forecast of 7.07 USD and a high forecast of 14.7 USD.

Lowest Forecast
Price Target
7.07 USD
171% Upside
Average Forecast
Price Target
9.52 USD
265% Upside
Highest Forecast
Price Target
14.7 USD
463% Upside
Aytu Biopharma Inc Competitors:
Price Targets

Revenue
Forecast

43% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
43% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 9 years, the compound annual growth rate for Revenue has been 43%. The projected CAGR for the next 3 years is 13%.

Operating Income
Forecast

N/A
Past Growth
17% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
N/A
Past Growth
17% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

The compound annual growth rate for Operating Income over the next 3 years is 17%.

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-89%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-89%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is AYTU's stock price target?
Price Target
9.52 USD

According to Wall Street analysts, the average 1-year price target for AYTU is 9.52 USD with a low forecast of 7.07 USD and a high forecast of 14.7 USD.

What is the Revenue forecast for Aytu Biopharma Inc?
Projected CAGR
13%

Over the last 9 years, the compound annual growth rate for Revenue has been 43%. The projected CAGR for the next 3 years is 13%.

What is the Operating Income forecast for Aytu Biopharma Inc?
Projected CAGR
17%

The compound annual growth rate for Operating Income over the next 3 years is 17%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett